俄勒冈州立大学研究人员开发了一种新型纳米粒子疗法，用甘露糖涂层帮助药物穿过血脑屏障，针对胶质母细胞瘤——一种最致命的脑癌进行治疗[1]。该疗法在小鼠实验中取得显著成效，动物的中位生存期增加了50%[1]，肿瘤明显缩小，且未观察到明显的器官毒性[1]。
这一治疗方法通过纳米粒子递送mRNA，使其能够恢复肿瘤细胞中PTEN肿瘤抑制蛋白的表达[1]。研究发现，纳米粒子表面的甘露糖涂层覆盖率相比对照组提高了6倍[1]，这种改进使得药物更容易靶向胶质母细胞瘤细胞——这类细胞的GLUT1表达水平是正常脑组织的3倍[1]。该研究已发表在《药物控释杂志》2026年第396卷[1]，并获得美国国家癌症研究所、尤尼斯·肯尼迪·施赖弗国家儿童健康与人类发展研究所和韩国国家研究基金会的支持[1]。
Researchers at Oregon State University have developed a novel nanoparticle therapy coated with mannose to treat glioblastoma, the most lethal form of brain cancer.[1] The treatment delivers messenger RNA to tumor cells via nanoparticles engineered to cross the blood-brain barrier, aiming to restore expression of the PTEN tumor suppressor protein.[1] In mouse studies, the therapy increased median survival by 50% and shrank tumors while producing no significant organ toxicity.[1]
The research team, led by Oleh Taratula, Olena Taratula, and Yoon Tae Goo, enhanced the mannose coating on nanoparticle surfaces by sixfold to improve delivery efficiency.[1] This approach exploits the fact that glioblastoma cells express the glucose transporter GLUT1 at three times the level found in normal brain tissue, allowing the sugar-coated particles to target cancer cells more effectively.[1] The findings were published in the Journal of Controlled Release, Volume 396, in 2026, and were supported by the National Cancer Institute, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Research Foundation of Korea.[1]